MedWatch

Genmab preparing for busy 2018

Next year, Genmab expects to obtain an approval of the company’s prize asset Darzalex for first-line therapy of multiple myeloma and provide the first data in solid tumors during the summer. Moreover, the company’s pipeline is in for a busy year, when the number of clinical candidates will double from two to four and a potentially pivotal study of the leading candidate will be initiated.

Foto: Carsten Bundgaard

The Danish biotech company Genmab owes the previous years’ success to its wonder drug Darzalex.

On a conference call following Genmab’s Q3 interim report, CEO Jan van de Winkel expresses his expectations to take the drug one step further in 2018. At the same time, the company’s pipeline of experimental drugs is starting to take shape and it gives the CEO even more hope for the future.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier